TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+6.18%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.03B
AUM Growth
+$2.03B
(+87%)
Cap. Flow
+$850M
Cap. Flow
% of AUM
41.76%
Top 10 Holdings %
Top 10 Hldgs %
48.77%
Holding
95
New
29
Increased
37
Reduced
1
Closed
2
Top Buys
| 1 |
Gilead Sciences
GILD
|
$105M |
| 2 |
CELG
Celgene Corp
CELG
|
$104M |
| 3 |
Pfizer
PFE
|
$46.3M |
| 4 |
Johnson & Johnson
JNJ
|
$34.9M |
| 5 |
AbbVie
ABBV
|
$27.8M |
Top Sells
| 1 |
FRX
FOREST LABORATORIES INC
FRX
|
$10.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$2.27M |
| 3 |
AEGR
Aegerion Pharmaceuticals, Inc.
AEGR
|
$1K |
Sector Composition
| 1 | Healthcare | 85.81% |
| 2 | Real Estate | 2.51% |
| 3 | Financials | 1.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Community Health Systems
CYH
$392M
| $8.47M | 0.4% |
+187,153
| New | +$8.47M |
|
52
Ventas
VTR
$30.7B
| $8.45M | 0.4% |
+119,430
| New | +$8.45M |
|
53
Sabra Healthcare REIT
SBRA
$4.56B
| $8.35M | 0.39% |
+343,390
| New | +$8.35M |
|
54
HCA Healthcare
HCA
$95.4B
| $8.16M | 0.38% |
+115,688
| New | +$8.16M |
|
55
Sangamo Therapeutics
SGMO
$161M
| $8.09M | 0.38% |
750,100
+629,700
| +523% | +$6.79M |
|
56
Zimmer Biomet
ZBH
$20.8B
| $8.02M | 0.38% |
+82,194
| New | +$8.02M |
|
57
Stryker
SYK
$149B
| $7.74M | 0.36% |
+95,840
| New | +$7.74M |
|
58
Medical Properties Trust
MPW
$2.66B
| $7.69M | 0.36% |
+627,274
| New | +$7.69M |
|
|
STJ
59
DELISTED
St Jude Medical
STJ
| $7.37M | 0.35% |
+122,510
| New | +$7.37M |
|
60
Sarepta Therapeutics
SRPT
$1.98B
| $7.29M | 0.34% |
+345,400
| New | +$7.29M |
|
61
Heron Therapeutics
HRTX
$204M
| $7.28M | 0.34% |
873,940
| – | – |
|
62
Revvity
RVTY
$9.68B
| $7.22M | 0.34% |
165,495
| – | – |
|
63
UnitedHealth
UNH
$279B
| $7.18M | 0.34% |
83,186
| – | – |
|
64
Idexx Laboratories
IDXX
$50.7B
| $6.63M | 0.31% |
112,530
| – | – |
|
65
Celldex Therapeutics
CLDX
$1.57B
| $6.59M | 0.31% |
+33,893
| New | +$6.59M |
|
|
NPSP
66
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $6.21M | 0.29% |
238,900
+156,000
| +188% | +$4.06M |
|
|
BLUE
67
DELISTED
bluebird bio
BLUE
| $6.21M | 0.29% |
13,350
+9,141
| +217% | +$4.25M |
|
|
AMRN
68
Amarin Corp
AMRN
$311M
| $6.15M | 0.29% |
282,171
+231,921
| +462% | +$5.06M |
|
|
ELGX
69
DELISTED
Endologix Inc
ELGX
| $5.84M | 0.27% |
+55,100
| New | +$5.84M |
|
|
WCG
70
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.35M | 0.25% |
+88,652
| New | +$5.35M |
|
71
Accuray
ARAY
$165M
| $5.31M | 0.25% |
731,943
| – | – |
|
|
MACK
72
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $4.99M | 0.23% |
72,166
| – | – |
|
73
Centene
CNC
$14.8B
| $4.96M | 0.23% |
240,000
| – | – |
|
74
Alnylam Pharmaceuticals
ALNY
$58.6B
| $4.81M | 0.23% |
61,595
| – | – |
|
|
CLVS
75
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.72M | 0.22% |
104,051
+56,687
| +120% | +$2.57M |
|